In a poignant turn of events, Jon Medved, one of Israel’s most renowned venture capitalists and the founder of OurCrowd, has been diagnosed with ALS (Amyotrophic Lateral Sclerosis), a progressive neurodegenerative disease.
In what may be his final public interview, as reported by TechCrunch, Medved shared how the very health tech innovations he supported years ago are now enhancing his quality of life.
From Investor to Beneficiary: Medved’s Journey with ALS
Medved’s career as a VC has been marked by a keen eye for transformative technologies, particularly in the health sector, long before his personal health challenges emerged.
His early investments in health tech startups, which focused on neurodegenerative diseases, have now come full circle, offering him tools and solutions to manage the debilitating effects of ALS.
A Legacy of Innovation in Israel’s Tech Ecosystem
Medved’s contributions to Israel’s startup scene through OurCrowd, a leading crowdfunding platform, have positioned him as a pivotal figure in fostering global tech advancements.
His decision to step down as CEO in October 2025, citing medical reasons, and transition to Chairman, reflects his determination to continue influencing the industry despite personal adversity.
The Impact of Health Tech on ALS Patients
The technologies Medved once backed are not only aiding him but also hold promise for millions of ALS patients worldwide, offering hope for better symptom management and improved daily living.
These innovations include assistive devices and potential therapies that could slow disease progression, a testament to the far-reaching impact of his investment foresight.
Looking Ahead: The Future of ALS Treatment
As research in Israel continues to break ground, with institutions like Tel Aviv University developing novel therapies, Medved’s story underscores the urgent need for sustained investment in health tech.
His personal battle with ALS serves as a powerful reminder of how venture capital can drive solutions that address some of humanity’s most pressing challenges.
For Medved, the intersection of his professional legacy and personal struggle highlights a unique narrative of resilience, innovation, and hope for the future of neurodegenerative disease treatment.
Andrew Lee
